

Review

Chemistry and pharmacology of *withania somnifera*: An update

Vikas Kumar^{1,*}, Amitabha Dey¹, Mallinath B. Hadimani², Tatjana Marcović³, Mila Emerald⁴

¹Neuropharmacology Research Laboratory, Department of Pharmaceutics, Indian Institute of Technology (Banaras Hindu University), Varanasi-221005, India; ²Department of Chemistry, Graduate School of Arts and Sciences, Wake Forest University, Winston-Salem, North Carolina 27106, USA; ³Institute of Medicinal Plant Research “Dr Josif Pančić” Belgrade, Tadeuša Košćuška 1, 11000 Belgrade, Republic of Serbia; ⁴Phytoceuticals International, Oxford Street East, London, Ontario, N5Y 1A0, Canada

ABSTRACT

Withania somnifera (Ashwagandha) is an important Rasayana herb and widely considered as Indian ginseng in Ayurveda. In traditional system of Indian medicine, it is used as tonic to rejuvenate the body and increase longevity. In Ayurvedic preparations, various parts of the plant have been used to treat variety of ailments that affect the human health. However, dried roots of the plant are widely used for the treatment of nervous and sexual disorders. The major active chemical constituents of this plant are withanolides, which is responsible for its wide range of biological activities. Since the beginning of the 20th century, a significant amount of research has been done and efforts are ongoing to further explore other bioactive constituents, and many pharmacological studies have been carried out to describe their disease preventing mechanisms. In this chapter, we have reviewed the chemistry and pharmacological basis of *W. somnifera* in various human ailments.

Keywords Ashwagandha, withanolides, adaptogen, anticancer, neuroprotective, antiinflammatory, Spermatogenic

INTRODUCTION

Withania somnifera (L.) Dunal (*W. somnifera*; Solanaceae), popularly known as 'Ashwagandha' in Sanskrit and as 'Indian ginseng', in Ayurveda (Kulkarni and Dhir, 2008; Puri, 2003). It is a green woody shrub of 200-800 cm height, found throughout the drier parts of South East Asia including India, Bangladesh, Sri-Lanka, Nepal and Pakistan, and different other parts of Australia, Africa and America (Hepper, 1991; Ilayperuma et al., 2002; Mabberley, 2008; Mirjalili et al., 2009). In India, it is widely distributed in the provinces of Madhya Pradesh, Uttar Pradesh, Punjab Gujarat and Rajasthan (Kulkarni and Dhir, 2008). It is an important Rasayana herb used in the traditional system of medicine, for more than 2500 years (Bhattacharya and Muruganandam, 2003). In Ayurvedic preparations, various parts of the plant have been used to treat variety of ailments (Kulkarni and Dhir, 2008), however roots of the plant is used to prepare tonic which promote longevity, revitalizing the body, arresting the aging process and augmenting defense against infectious diseases (Bhattacharya and Muruganandam, 2003; Singh et al., 2008). *W. somnifera* also participate as an important ingredient in many Ayurvedic formulations, which are currently commercialized in India and other countries. Ayurvedic formulations containing *W. somnifera* prescribed as analgesic for a variety of musculoskeletal disorders (arthritis and rheumatism), certain forms of hypertension, for stimulating sexual impulses and

increases sperm counts, in gynecological practice for vaginitis and during pregnancy for breast development (Mishra and Singh, 2005; Puri, 2003). Since ancient times *W. somnifera* has been considered for persons of both sexes, of all ages and at all stages of their lives as nerve tonic, aphrodisiac, adaptogen, antirheumatic agent, astringent and memory enhancer (Bhattacharya and Muruganandam, 2003; Puri, 2003). Many pharmacological studies have been carried out to describe multiple biological properties of *W. somnifera* and outcomes obtained from these studies indicate that it is also useful to treat bronchitis, asthma, ulcer, cancer, emaciation, insomnia, and senile dementia (Kulkarni and Dhir, 2008; Mishra and Singh, 2005). *W. somnifera* also having other multipurpose medicinal uses which are supported by different preclinical and clinical trials includes for antidiabetic, immunomodulatory, hemopoietic, neurological inflammatory disorders and Parkinson's disease, additionally it is also useful as antioxidant, abortifacient, antibiotic, aphrodisiac, deobstruent, diuretic and sedative (Bone, 1996; Kulkarni and Dhir, 2008; Mishra and Singh, 2005). Its chemopreventive properties make it a potentially useful adjunct for patients receiving radiation and chemotherapy (Devi et al., 1992).

The major biochemical constituents of *W. somnifera* are withanolides (steroidal lactones with ergostane skeleton). The withanolides have C28 steroidal nucleus with C9 side chain, having a six membered lactone ring. Withanolides are highly oxygenated phytochemicals, and the oxidation at various sites of skeleton is responsible for the structural variations in different classes of withanolides (Choudhary et al., 2013; Kulkarni and Dhir, 2008). In addition, different classes of withanosides, glycowithanolides, sitoindosides, alkaloids, saponins, amino acids, phenolic compounds, flavonoids and many other secondary bioactive metabolites of the plant with broad-spectrum therapeutic activity were isolated and characterized (Elsakka et al., 1990; Mishra and Singh, 2005).

*Correspondence: Vikas Kumar

E-mail: vikas.phe@iitbhu.ac.in

Received October 5, 2014; Accepted February 24, 2015; Published February 28, 2015

doi: <http://dx.doi.org/10.5667/tang.2014.0030>

© 2015 by Association of Humanitas Medicine

This is an open access article under the CC BY-NC license.

(<http://creativecommons.org/licenses/by-nc/3.0/>)

Much of ashwaganda's pharmacological activity has been attributed to two main constituents such as withaferin-A and withanolide-D (Mirjalili et al., 2009).

Extensive toxicological studies and the data obtained from various clinical research works on *W. somnifera* was demonstrated that the plant is nontoxic in wide range of practical doses and it can be assumed that the doses in which its preparations are indicated in humans are expected to be very safe. As of today, no herb-herb or herb-drug interactions has been reported in the literature with *W. somnifera* (Kulkarni and Dhir, 2008; Prabu et al., 2013; Sharada et al., 1993). The side effects and the long-term safety of *W. somnifera* are still under construction. However, large doses of *W. somnifera* might cause stomach upset, diarrhea, and vomiting. Based on limited human research it was reported that *W. somnifera* may cause sedation, possible life-threatening respiratory depression, decrease blood pressure and cause abnormal heart rhythms (Gardner and McGuffin, 2013; Puri, 2003).

Information now available on chemistry and pharmacology of diverse types of *W. somnifera* extracts obtained from different parts of the plant have been reviewed which strongly suggest that appropriate combinations with other plants could be used for prevention and cure of diverse disorders and chronic diseases. In this chapter, we mainly focus on earlier and recent advancements on chemistry and pharmacological aspects of *W. somnifera*.

Chemistry

The major chemical constituents of *W. somnifera* are

withanolides, a group of naturally occurring C28 steroidal lactones with ergostane-based skeleton. Withanolides are highly oxygenated phytoconstituents, and the oxidation at various sites of skeleton is responsible for the structural variations in different classes of withanolides. Withanolides possess a wide range of biological activities (Choudhary et al., 2013). Lavie and coworkers in 1965 were the first to isolate withaferin-A from *W. somnifera* (Lavie et al., 1965). Even though several reports were published in the recent literature from various research groups about evaluating different pharmacological activities of *W. somnifera*, very few groups have reported synthetic analogs or semi-synthetic derivatives of its potential alkaloids. Most of the analogs synthesized are the derivatives of its chief constituent withaferin-A. Here we will briefly review some of the most important developments in recent years involving chemical modification of Withanolides.

Gunatilaka group reported the synthesis and cytotoxic profile of various derivatives of withaferin-A (Wijeratne et al., 2014). They synthesized a total of 36 analogs by a variety of chemistry and compared their cytotoxicity to cytoprotective heat-shock-inducing activity to that produced by withaferin-A. By analyzing structure activity relationship for this structurally diverse group of compounds, they have found that ring anone of withaferin-A is essential for its bioactivity. Acetylation of hydroxyl group at the 27th position leads to the loss of potency. Their detailed studies demonstrate that the basic withanolide skeleton can be modified to selectively enhance heat shocking inducing activity (Figs. 1 and 2).

Namboothiri group has reported the total synthesis of three pyrazole containing withasomnine based alkaloids (Varma et al., 2013). Starting with 4-nitro-1-butanol and commercially available aldehydes, they synthesized these molecules in




Fig. 1. Withanolides and their Derivatives (1-26) Reported by Gunatilaka Group.




Fig. 2. Withanolide Derivatives Prepared by Chemical and Microbiological Transformations (27-38).





Fig. 3. Synthesis of Withasomnine Derivatives (40) by 1,3-Dipolar Cycloaddition Reaction.



Entry	R
40a	4-OMePh
40b	4-OHPh
40c	4-ClPh
40d	2-furyl
40e	-cyclohexyl
40f	4-NO ₂ Ph

Fig. 4. Withasomnine (39) and its Derivatives (40a-f).




Fig. 5. Withaferin-A (41) and Withalongolide-A (42).

overall five steps. A wide variety of methods has been reported in the earlier literature but these methods involve complex chemistry and lower yields. The work of Namboothiri group is more efficient in terms of its reaction conditions, yields and availability of starting chemicals. The key step in these syntheses is a 1,3-dipolar cycloaddition of α -bromopropyl nitroalkenes with commercially available TMSCHN₃ (Fig. 3).

With this novel method, they were able to accomplish the total synthesis of three withasomnine natural products (39 and 40a-b), and three other non-natural analogs (40c-f) (Fig. 4).

Aubé and coworkers reported a series of semisynthetic analogs of withalongolide-A, which is a C-19 hydroxylated analog of withaferin-A (Motiwala et al., 2013). These semisynthetic derivatives are found to be more cytotoxic than the parent molecule against a variety of cell lines (Fig. 5).

A series of aliphatic esters (43a-e) were synthesized by

slight modification of standard acylation procedure with acetic anhydride. These researchers were able to isolate both mono and diacetate derivatives from one-pot reactions (Fig. 6).

In a second set of compounds they developed benzoyl esters (44a-d) by reaction of withalongolide-A with *p*-chlorobenzoylchloride (Fig. 7). Another interesting molecule developed was a steroidal macrocycle, compound (45). This 14-membered macrocycle with *E*-configuration was obtained by bis-acylation of withalongolide-A monoacetate with 4-pentenoic anhydride followed by ring closing metathesis using Grubb's II catalyst (Fig. 8).

All these synthesized molecules were tested for cytotoxic properties against four different cell lines. Some of these semi synthetic derivatives are found to be more potent than the parent natural molecules.




Fig. 6. Acetylated Derivatives of Withalongolide-A (43a-e).




Fig. 7. Benzoylated Derivatives of Withalongolide-A (44a-d).




Fig. 8. Macrocycle Derivative of Withalongolide-A (45).

Recently Darokar group developed a series of derivatives with specific modifications at carbons 5, 6 and 7 of ring B (Joshi et al., 2014). In addition, they selectively converted the epoxide group to a thiirane, an amino alcohol and alcohol group, and all these derivatives were evaluated against four different cancer cell lines (Fig. 9).


These researchers have successfully demonstrated that a wide variety of chemistry can be applied to withanolides, and these chemical modifications have led to a decrease in cytotoxic potency.

The reports presented here firmly establish the robust nature of withaferin-A, that can be modified chemically leading to a wide variety of biologically active novel molecules. These various structural analogs of withanolides help us understand structure-activity relationships among these varied structures. Whether these novel molecules will hold any potential for the treatment of diseases other than cancer, need to be studied.

Pharmacology

Anticancer activity

Numerous studies published over the last two decades indicate that *W. somnifera* has unique characteristics to suppress various types of cancer and it has been used as Ayurvedic remedy for



Entry	R	R ₁	R ₂
46a	OH	H	NHCH ₂ Ph
46b	H	H	NHCH ₂ Ph
46c	OH	OH	NHCH ₂ Ph
46d	H	OH	NHCH ₂ Ph
46e	OH	H	NH(CH ₂) ₃ CH ₃
46f	H	H	NH(CH ₂) ₃ CH ₃
46g	OH	OH	NH(CH ₂) ₃ CH ₃
46h	H	OH	NH(CH ₂) ₃ CH ₃

Fig. 9. Withanolide Derivatives Prepared by Aminolysis of Epoxides (46 a-h).

the treatment of various types of cancer over two thousand years. Ashwagandha possesses anticancer properties against prostate, colon, lung, breast, leukemia, pancreatic, renal, head and neck cancer cells of humans (Nema et al., 2013; Patel et al., 2013; Singh et al., 2011; Yadav et al., 2010), forestomach and skin cancer cells in mice (Padmavathi et al., 2005). Recently the anticancerous potential of *W. somnifera* and its bioactive withanolides has been extensively studied by several research groups all around the world, which have discovered diverse mechanisms such as cytotoxicity, cell differentiation induction, cancer chemoprevention, cyclooxygenase-2 (COX-2) inhibition and a potential to inhibit the enzyme quinone reductase. These withanolides are highly oxygenated natural bioactive constituents which are responsible for ashwagandha's biological properties including antitumor activity (Mulabagal et al., 2009; Patel et al., 2013).

Withaferin-A, is a potent inhibitor of angiogenesis and thus protective in certain types of cancers (Patel et al., 2013). Recent investigation identifies that *W. somnifera* enriched withaferin-A induces apoptosis through mechanisms (Fig. 10) such as, inhibiting the activation of nuclear factor kappa-B (NF-κB) by preventing the TNF-induced activation of IκB kinase β via a thioalkylation sensitive redox mechanism (Oh and Kwon, 2009), activation of tumor suppressor proteins such as p53 and pRB (Wadhwa et al., 2013). It increases reactive oxygen species (ROS) generation, Par-4 induction and p38 MAP kinase activation to induce programmed cell death (Patel et al., 2013). It also inhibits the Notch signaling pathway and NF-κB activation, induces Akt inactivation, death receptor 5 up-regulation and down-regulation of cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (Oh and Kwon, 2009; Patel et al., 2013; Um et al., 2012).

In a separate study on human cancer cells, the active withaferin-A from *W. somnifera* exhibits its cytotoxicity through Par-4 induction, through inhibition of chymotrypsin




Fig. 10. Withaferin-A induced cell apoptosis mechanisms.

like activity of proteasome, and by covalently modifying the cysteine residue of intermediate filament protein vimentin. In addition, withaferin-A also induces actin microfilament aggregation by targeting Annexin-II (Yang et al., 2013; Yu et al., 2010). On prostate cancer cells, withaferin-A arrests G2/M phase cell cycle and prevents mitosis by up regulation of phosphorylated Wee-1, phosphorylated histone H3, p21, and Aurora B targets. On the other hand, down regulation of cyclins (A2, B1, and E2) and a reduction in phosphorylated cyclin-dependent kinase (Cdc2) (Tyr15) were observed in *in vitro* studies and this suggests that activation of Cdc2 leads to arrest in the M phase of cell cycle, with abnormal duplication and initiation of mitotic catastrophe that result in cell death (Roy et al., 2013). Withaferin-A also possesses its apoptotic action on human colon cancer cells through inhibition of Notch-1 signaling pathway and down regulating pro-survival pathways, such as Akt/NF- κ B/Bcl-2, in three colon cancer cell lines (HCT-116, SW-480, and SW-620). It also induces apoptosis on colon cancer cells by other mechanisms like generating ROS (Koduru et al., 2010). In addition, it also induces apoptosis in human breast cancer cells by mechanisms, such as inhibition of cell migration/invasion through down regulation of signal transducer and activator of transcription (STAT3) activity (Patel et al., 2013). Suppression of X-linked inhibitor of apoptosis protein and cIAP-2 protein, and reduction in the survivin protein levels are also the common targets for withaferin-A to induce apoptosis on human breast cancer cells (MDA-MB-231 and MCF-7) (Hahm and Singh, 2013). In a recent study, it was shown that withaferin-A inhibits the vimentin cytoskeleton through perinuclear vimentin accumulation followed by rapid vimentin depolymerization and a concomitant induction of vimentin ser 56 phosphorylation to induce apoptosis on human breast cancer cells (Thaiparambil et al., 2013). Withaferin-A also reportedly increases ROS production due to inhibition of mitochondrial respiration resulting in apoptosis induction of breast cancer cells (MDA-MB-231 and MCF-7) (Hahm et al., 2011). An investigation with malignant pleural mesothelioma (MPM) cells, indicates that withaferin-A inhibited growth of the MPM cells both in murine and human by decreasing the chymotryptic activity of the proteasome that results in elevation of ubiquitinated protein levels and pro-apoptotic proteasome target proteins (p21, Bax, I κ B α). The apoptosis of MPM cells

was induced by activation of pro-apoptotic p38 stress activated protein kinase and caspase-3, elevated levels of pro-apoptotic Bax protein and cleavage of poly-(ADP-ribose)-polymerase (Yang et al., 2012). Withaferin-A also causes cytotoxicity in human renal carcinoma Caki cells, where studies show that it inhibits interleukin (IL)-6 induced phosphorylation of STAT3 via Tyr705 residue that resulted in reduction of Janus-activated kinase 2 activities. Withaferin-A also down-regulates the expression of STAT3 regulated genes such as Bcl-xL, Bcl-2, cyclin D1 and surviving which leads to cell apoptosis (Um et al., 2012). In pancreatic cancer cell lines (Panc-1, MiaPaCa2 and BxPc3), withaferin A inhibits Hsp90 chaperone activity through an ATP independent mechanism, resulting in Hsp90 client protein degradation thus acting against pancreatic cancer (Yu et al., 2010). In a variety studies, it was observed that *W. somnifera* significantly changed the levels of leucocytes, lymphocytes, neutrophils and immunoglobulins in experimental colon cancer in mice induced by azoxymethane (Muralikrishnan et al., 2010a). It was also observed that *W. somnifera* decreased the activities enzymes such as isocitrate dehydrogenase, succinate dehydrogenase, malate dehydrogenase and alpha-keto glutarate dehydrogenase in colon cancer bearing animals, leading to lack of nutrition of cancerous cells resulting in cell death (Muralikrishnan et al., 2010b). In high concentration, water extract of ashwagandha leaves induces apoptosis, cytotoxicity and cell death of human (YKG1, A172, U118MG) and rat (C6) glioma cell lines (Kataria et al., 2011). Although both, withaferin-A and withanolides are extracted from *W. somnifera*, withaferin-A is the most potent anticancer compound than withanolides (Kapoor, 2014). The results of the various findings have discovered that, *W. somnifera* and its chemical ingredients are effective in the prevention and treatment of several kinds of cancers including colon cancer, lung cancer, blood cancer, skin cancer, breast cancer, renal cancer, fibrosarcoma, prostate cancer and pancreatic cancer.

Neuroprotective activity

Preclinical research and clinical trials support the use of *W. somnifera* for the treatment of neurological conditions such as anxiety, depression, cognitive disorders, senile dementia and neurodegenerative disorders (Alzheimer's and Parkinson's




Fig. 11. Neuroprotective mechanisms of *Withania somnifera*.

diseases). Earlier, it was reported that the neuroprotective activity of *W. somnifera* root extract could be because of presence of glycowithanolides and their ability to inhibit lipid peroxidation because of their antioxidant actions. In addition, withanolides and sitoindosides (VII–X) also augment catalase and glutathione peroxidase activities in rat frontal cortex and striatum. *W. somnifera* was also found to improve the cognitive capabilities of the brain by increasing the cortical muscarinic acetylcholine capacity in lateral septum and frontal cortex, which suggest their capacity to affect events in the cortical cholinergic-signal transduction cascade (Schliebs et al., 1997). The pharmacological studies suggested that *W. somnifera* improves the athletic performance via increasing the hemoglobin count and red blood cell count, which leads to an increase in the capacity of blood to transport oxygen at a greater capacity to the peripheral system (Shenoy et al., 2012). It has been shown that *W. somnifera* improves endurance performance in healthy individuals at a moderate intensity of 65% VO₂ max (Sandhu, 2010). *W. somnifera* which is rich in proteins, amino acids (glycine, alanine, tyrosine, aspartic acid, tryptophan, glutamic acid, cysteine, etc.), starch, reducing sugars, alkaloids, steroidal lactones possess an amazing nutritional value and acts as a tonic, stimulant and energy rejuvenator. Studies also revealed that, phenolic compounds present in the root of *W. somnifera* play an important role on overall antioxidant activities of the plant (Bhatnagar et al., 2009).

Recent research developments in this area show different mechanisms (Fig. 11) that help us understand the neuroprotective activity of *W. somnifera* and its bioactive withanolides.

One such report has revealed that, *W. somnifera* root extract down-regulates nitric oxide production that significantly inhibits the stress induced NADPH-diaphorase activation in the brain via suppressing corticosterone release and activating cholineacetyltransferase. This pathway is thought to be the main mechanism underlying the neuroprotective effects of *W. somnifera* (Bhatnagar et al., 2009). In another study *W. somnifera* root extract significantly increases the levels of brain

antioxidant enzymes (superoxide dismutase (SOD), chloramphenicol acetyltransferase, glutathione, and glutathione S-transferase) and total proteins to protect the brain when animal was exposed to lead nitrate (Sharma et al., 2011). Another report also revealed that withanolide-A isolated from roots of *W. somnifera* at a dose 10 µmol kg⁻¹ could regenerate neurites and reconstruct synapses in severely damaged neurons which has a huge potential in the treatment of diabetic neuropathy (Kuboyama et al., 2005). There is a scarcity of experimental data on the potential neuroprotective effects of *W. somnifera* against β-amyloid induced neuropathogenesis. However, *in vitro* studies with human neuronal SK-N-MC cell lines show that *W. somnifera* reverses the toxic effects when cells are intoxicated with β-amyloid (1-42) and HIV-1_{Ba-L} (clade B) infection (Kurapati et al., 2013). Computational docking evidences reveal that withanolide-A inhibits brain acetyl cholinesterase, which could be a therapeutic alternative for the treatment of neurodegenerative Alzheimer's disease (Grover et al., 2012). The root of *W. somnifera* enriched with withanolides and withanosides reversed behavioral deficits, plaque pathology, accumulation of β-amyloid peptides and oligomers in the brains of middle-aged and old amyloid precursor protein/the presenilins Alzheimer's disease transgenic mice, results of this study indicates that *W. somnifera* increases the transport of β-amyloid peptides from the brain to the periphery. It also enhances the expression of low-density lipoprotein receptor-related protein in brain microvessels and the β-amyloid peptide-degrading protease neprilysin (Sehgal et al., 2012). *W. somnifera* and its bioactive withanolides are also effective in treating Parkinson's disease, where it was revealed that its root extract enhances brain dopamine level in Parkinson's animals and also improves physiological abnormalities seen in Parkinson's disease. *W. somnifera* improves the condition of lipidperoxidation, reduced glutathione content, activities of glutathione-S-transferase, glutathione reductase, glutathione peroxidase, superoxide dismutase and catalase, catecholamine content, dopaminergic D2 receptor binding affinity and tyrosine hydroxylase expression (RajaSankar et al., 2009). Supplement with L-Dopa

W. somnifera were also effective in inhibiting haloperidol-induced catalepsy in mice (Girdhari et al., 2009). Randomized controlled clinical trial with *W. somnifera* root powder (3 g/day) also shows effectiveness in treating Parkinson's disease in four weeks treatment. The results of the various findings described that, *W. somnifera* and its chemical ingredients are effective in prevention of neurodegenerative disorders and protect neurons from oxidative damages.

Antiepileptic activity

W. somnifera is traditionally used for the treatment of epilepsy and seizures. Various *in vitro* and *in vivo* preclinical studies have provided enough evidence for the use of *W. somnifera* against various types of epilepsy. In general, studies with rodent models show that *W. somnifera* and its bioactive withanolides are effective in reducing seizures through various mechanisms. One such mechanism involved the GABA_A receptor modulation in brain, where sub-effective dose of *W. somnifera* (50 mg/kg), with a sub-protective dose of either GABA (25 mg/kg) or Diazepam (0.5 mg/kg) increases the seizure threshold in brain (Kulkarni et al., 2008). In another study, it was demonstrated that *W. somnifera* root extract and withanolide-A were capable of restoring spatial memory deficit by inhibiting oxidative stress induced alteration in glutamergic neurotransmission, where *W. somnifera* reduces the expression of N-methyl-D-aspartate (NMDA) receptor, which is responsible for spatial memory loss in epileptic rats (Soman et al., 2012). Leaf extracts of *W. somnifera* were also showing its protective action against glutamate induced toxicity in human neuroblastoma (IMR-32) cells, by inhibiting over expression of stress protein 70 kilodalton heat shock proteins (Kataria et al., 2012). In another study it was found that *W. somnifera* root extract and withanolide-A regulate the expression and function of α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor and glutamate levels in brain dopaminergic nervous system and results are attributed to improvement in motor learning in pilocarpine-induced temporal lobe epilepsy model (Soman et al., 2013). These findings reveal that *W. somnifera* and its bioactive withanolides have anti convulsant potential and are useful in treating various types of epilepsy.

Antidepressant and antianxiety activity

The roots of *W. somnifera* are used extensively in Ayurveda for the treatment of anxiety and depression. Earlier it was reported that, anxiolytic-antidepressant potential of *W. somnifera* and its glycowithanolides (Bhattacharya et al., 2000). Recent study reports also support the use of *W. somnifera* for depression and anxiety disorders. In a very recent study, it is found that *W. somnifera* at 40 mg/kg significantly reduces the depression in various experimental models (Jayanthi et al., 2012). Clinical trials with healthy volunteers also revealed that aqueous extracts of *W. somnifera* improve the psychomotor performances in anxiety and depression (Pingali et al., 2014). It was assumed that *W. somnifera* reduces the production of nitric oxide in the brain tissues, resulting in its anxiolytic activity (Khan and Ghosh, 2011; Maity et al., 2011). Study findings explained that *W. somnifera* and its bioactive withanolides possesses antidepressant and antianxiety potential and are useful in treating various types of mental disorders.

Antiinflammatory and antiarthritic activity

W. somnifera exhibits potent antiarthritic and antiinflammatory activities. Antiinflammatory activity has been characteristic to biologically active steroids, of which withaferin-A is a major component. Recent studies revealed that *W. somnifera* at dose

levels 600 & 800 mg/kg significantly decreased the severity of arthritis by effectively suppressing the inflammatory mediators and improving the functional recovery of motor activity in experimental animals (Gupta and Singh, 2014). Roots of *W. somnifera* and withanolides are also effective in treating arthritic inflammation, inflammation in cystic fibrosis and irritable bowel syndrome, through various mechanisms such as inhibiting NF- κ B activation, inhibition of COX-2 generation, inhibition of endothelial cell protein C receptor through antioxidant effect and cytokines release, thus in turn causes depletion of inflammatory mediators (Ku et al., 2014; Mulabagal et al., 2009; Oh and Kwon, 2009). *W. somnifera* and its bioactive withaferin-A down regulate the production of inflammatory mediators like prostaglandins, histamine, interleukins and cytokines (Gupta and Singh, 2014; Paval et al., 2009). Withaferin-A has been shown to stimulate differentiation and growth of osteoblasts in menopausal osteoporosis and by bone injury, via increased expression of osteoblast-specific transcription factor and mineralizing genes (Khedgikar et al., 2013). Through all these mechanisms *W. somnifera* shows its antiinflammatory and antiarthritic activity, which makes it useful for the treatment of various inflammatory disorders. *W. somnifera* is also shown to possess analgesic activity in several rodent models and thus preferred for various pain management therapies (Sabina et al., 2009; Shahriar et al., 2014).

Spermatogenic activity

Several investigators reports have suggested that *W. somnifera* is beneficial in the treatment of male infertility. Experimental evidences have shown that treatment with *W. somnifera* induced testicular development and spermatogenesis in immature Wistar rats by directly affecting the seminiferous tubules, improved pro-sexual behavior of sexually sluggish mice, and increased testicular daily sperm production and serum testosterone level. *W. somnifera*, also counteract the oxidative damage to the sperm and reactive oxygen species associated with abnormal sperm parameters leading to infertility (Ambiye et al., 2013). In recent years, it has been well documented that *W. somnifera* improves semen quality by effectively reducing oxidative stress and improving reproductive hormone levels in infertile male patients (Ahmad et al., 2010; Shukla et al., 2011). In clinical trials with infertile male patients, *W. somnifera* repairs the altered concentrations of lactate, alanine, citrate, glycerylphosphorylcholine, histidine, and phenylalanine in seminal plasma, and it recovers the quality of semen of post-treated compared to pre-treated men, in addition to inducing spermatogenesis in infertile male patients (Ambiye et al., 2013; Gupta et al., 2013). *W. somnifera* boosts enzymatic activity of metabolic pathways and energy metabolism. These evidences support the use of *W. somnifera* for the treatment of male infertility.

Hepatoprotective activity

Various studies were performed to evaluate the hepatoprotective potential of *W. somnifera*. As it is used for various ailments, the hepatoprotective activity was also considered for its effective use. Investigations have given numerous evidences, where *W. somnifera* at a dose 500 mg/kg significantly reduces the elevated biomarkers (aspartate aminotransferase, alanine transaminase, alkaline phosphatase, and Bilirubin) in experimental animals when exposed to hepatotoxic dose of paracetamol. It significantly reduces the lipid peroxidation, enhances glutathione content, catalase, glutathione reductase and glutathione peroxidase activity in liver (Malik et al., 2013; Sabina et al., 2013). In another study, *W. somnifera* has shown its hepatoprotective activity against

gamma radiation induced toxicity in rodents, where 100 mg/kg dose of *W. somnifera* significantly decreases hepatic serum enzymes, levels of malondialdehyde, total nitrate/nitrite NO(x) and also heme oxygenase activity in liver. Serum antioxidant enzymes, including SOD and glutathione peroxidase in hepatic tissues were elevated (Hosny and Farouk, 2012). These study findings support the use of *W. somnifera* for various hepatic disorders.

Antimicrobial activity

The leaves and roots of *W. somnifera* have been shown to exhibit antimicrobial activity in recent studies. Leaf extracts at concentrations 6.25 mg/ml and 12.5 mg/ml inhibited the growth of five Gram-negative pathogenic bacteria (*Escherichia coli*, *Salmonella typhi*, *Citrobacter freundii*, *Pseudomonas aeruginosa* and *Klebsiella pneumonia*) (Alam et al., 2012). Isolated flavonoids and alkaloids from *W. somnifera* show growth inhibitory activity against *Enterobacter aerogens*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Bacillus subtilis*, *Klebsiella pneumoniae*, *Raoultella planticola* and *Agrobacterium tumefaciens* at concentration 0.039 mg/ml (Singh and Kumar, 2011; Singh and Kumar, 2012). In a separate study, crude extract of leaves of *W. somnifera* was tested against clinical pathogens *Staphylococcus aureus*, *Staphylococcus aureus*, *Streptococcus mutans*, *Streptococcus sobrinus* and *Salmonella paratyphi* B, where it was found that 100 µl of extracts (100 mg/ml) was able to inhibit the growth of all the pathogenic bacteria (Al-Ani et al., 2013; Pandit et al., 2013). The antimicrobial potency of *W. somnifera* was thought to be due to its antioxidant properties (Alam et al., 2012). The ascorbic acid, anthocyanin and polyphenols found in *W. somnifera* leaves could inhibit microorganisms via iron deprivation or hydrogen bonding with vital proteins such as microbial enzymes (Scalbert, 1991). *W. somnifera* reported to exhibit antibacterial activities and it shows its activity against both Gram-positive and Gram-negative pathogenic bacteria (Singariya et al., 2012). In another study, it was argued that *W. somnifera* shows its bactericidal and fungicidal activity through mechanisms attributed to cytotoxicity, gene silencing and immune potentiation, where aerial extract at concentration 1.56 mg/ml shows good antimicrobial potency (Mwitari et al., 2013). It is also shown to be a moderate to active against *Microsporum gypseum*, *Candida albicans* and *Cryptococcus neoformans* (Mwitari et al., 2013). Withanolide D, E and F showed potent activity against PknG target in *Mycobacterium tuberculosis* (Santhi and Aishwarya, 2011). It has also been shown in different studies that *W. somnifera* have the best antimicrobial (1.5625 mg/ml), immunopotentiality (2 times IL-7 mRNA expression) and safety level (IC₅₀ 200 mg/ml). Results of these findings reveal that extracts of *W. somnifera* and its bioactive constituents possess great antimicrobial potential against various test pathogenic microorganisms that can be exploited for future antimicrobial drugs for treating infectious diseases and could be an alternative for chemotherapy.

Hypoglycaemic and hypolipidemic activity

W. somnifera has long been used in traditional and Ayurvedic medicine to cure diabetes and obesity. Recent studies and observations have revealed that, flavonoids found in the roots of *W. somnifera* were able to reduce the high blood glucose level in experimental animals. It was also shown that *W. somnifera* at dose 100 mg/kg significantly reduces the blood glucose and lipid levels (Rajangam, et al., 2009). In another study, powder of *W. somnifera* at dose 200 mg/kg significantly reduces the blood glucose level. The blood glucose lowering activity of *W. somnifera* is thought to be its action on pancreatic

β-cells to stimulate the release of insulin. It was also found that *W. somnifera* and its glycowithanolides induce the transport of glucose into the cells, stimulate the release of insulin and increase the activity of GLUT transporters activity (Anwer et al., 2008; Khalili, 2009; Sarangi et al., 2013; Visavadiya and Narasimhacharya, 2007). In another study it was observed that, *W. somnifera* diet significantly increases plasma HDL-cholesterol levels, increases HMG-CoA reductase activity and bile acid content of liver in experimental animals (Visavadiya and Narasimhacharya, 2007). These observations support the traditional claims for the use of *W. somnifera* against diabetes and obesity.

Miscellaneous pharmacological activities

In recent years, numerous pharmacological studies were also carried out to explore other beneficial effects of *W. somnifera*. Further research with withaferin-A shows that having antiplatelet, anticoagulant, and profibrinolytic properties (Ku and Bae, 2014), cardioprotective activity, nephroprotective activity, immunomodulatory activity and antileishmanial activities. Details of various pharmacological activities are illustrated in Table 1.

CONCLUSION

In the ancient system of Indian medicine, *Withania somnifera* is used as Rasayana herb for more than 2500 years. In many Ayurvedic formulations that are currently commercialized in India and other countries, *W. somnifera* participate as an active ingredient and are prescribed for treating various ailments that affects human health. Different parts of the plant has also been widely studied for their various pharmacological activities like anticancer, neuroprotective, antioxidant, anxiolytic, antidepressant, adaptogen, memory enhancing, antiparkinsonian, antiinflammatory, and antitumor properties. Various other effects like immunomodulation, hypoglycemic, hypolipidemic, antibacterial, cardiovascular protection, or sexual behaviour have also been studied. Withanolides are among the most active constituents of *W. somnifera* with tremendous potential to treat various health disorders. The purification, structure characterization, and pharmacological studies on other classes of bioactive withanolides need further validation to support the traditional uses of withanolide-producing different parts of the plant to treat various ailments. Presence of diverse bioactive constituents and their low toxicity profiles, and novel mechanism of action makes ashwagandha a suitable drug candidate for the treatment of various diseases. However, there is a need of extensive research at the interface of chemistry and pharmacology to explore *W. somnifera* towards drug development with enhanced activity and lower toxicity, as compared to its available commercial formulations.

ACKNOWLEDGEMENTS

None.

CONFLICT OF INTEREST

The authors have no conflicting financial interests.

REFERENCES

Table 1. Reported pharmacological activities of *Withania somnifera*

Sl. No.	Part of plant	Type of extract	Pharmacological activity	Dose, duration and route of administration
1	Leaves	Aqueous extract	Anticancer	100 & 250 mg/kg, twice daily for 6 days, p.o.
2	Roots	Aqueous extract	Against Colon cancer	400 mg/kg, once in a week for 28 days, p.o.
3	Roots	Hydromethanolic extract	Antioxidant and Neuroprotective	200 & 500 mg/kg, for 42 days, p.o.
4	Roots	Dried powder	Against Forestomach and Skin carcinogenesis	2.5 & 5% (w/w) powdered root mixed with standard diet, for 14 days, p.o.
5	Roots	Aqueous extract	Neuroprotective	100, 200 & 400 mg/kg, for 28 days, p.o.
6	Roots	Chloroform : Methanol (1:1) extract	Against Alzheimer's disease	1000 mg/kg, for 60 days, p.o.
7	Roots	Aqueous extract	Antiparkinson's	100 mg/kg, for 28 days, p.o.
8	Roots	Aqueous extract	Against Catalepsy	20 & 50 mg/kg, for single day, p.o.
9	Roots	Aqueous extract	Anticonvulsant	100 & 200 mg/kg, for single day, p.o.
10	Roots	Aqueous extract	Antiepileptic	100 mg/kg, for 15 days, p.o.
11	Roots	Hydro-methanolic extract	Memory-enhancing	50, 100, 150, 200 & 250 mg/kg, for single day, p.o.
12	Roots	Capsule formulation	Anxiolytic	250 mg/capsule, twice daily for 14 days, p.o.
13	Roots	Aqueous extract	Antidepressant	100 & 150 mg/kg, for 14 days, p.o.
14	Roots	Aqueous extract	Antiinflammatory	600 & 800 mg/kg, for 25 days, p.o.
15	Roots	Alcoholic extract	Antiarthritic	100 mg/kg, for 20 days, p.o.
16	Roots	Alcoholic extract	Spermatogenic	225 mg/capsule thrice daily, for 90 days, p.o.
17	Roots	Dried powder	Spermatogenic	5 g/day with milk, for 90 days, p.o.
18	Roots	Aqueous extract	Hepatoprotective	500 mg/kg, for 6days/week for 28 days, p.o.
19	Roots	Dried powder	Hepatoprotective	500 & 1000 mg/kg, for single day, p.o.
20	Leaves, fruits and roots	Methanolic extract	Antioxidant and Antibacterial	<i>In vitro</i> (MIC-100 µg/ml)
21	Leaves and roots	Hydroalcoholic extract	Hypoglycaemic and Hypolipidaemic	100 mg/kg, for 56 days, p.o.
22	Leaves and roots	Aqueous extract	Hypoglycaemic and Hypolipidaemic	100 & 200 mg/kg, for 56 days, p.o.
23	Leaves	Aqueous extract	Antifungal	<i>In vitro</i> (MIC 10 mg/ml)
24	Roots	Hydroalcoholic extract	Antiviral	<i>In vitro</i> (25 µg/ml conc. shows 99.9% inhibition on Bursal Disease Virus Replication)
25	Roots	Methanolic extract	Antileishmanial	<i>In vitro</i> (IC ₅₀ value 78 ± 5 µg/ml against promastigote, and 63 ± 6 µg/ml against amastigote forms of <i>L. donovani</i>)
26	Roots	Aqueous extract	Cardioprotective	50 mg/kg, for 20 days, p.o.
27	Roots	Hydro-alcoholic	Cardioprotective	25, 50 and 100 mg/kg, daily for 28 days, p.o.
28	Roots	Aqueous extract	Immunomodulatory	200 mg/kg, for 42 days, p.o.
29	Roots	Aqueous extract	Nephroprotective	500 mg/kg, for 22 days, p.o.
30	Roots	Aqueous extract	Nephroprotective	350 mg/kg, for 15 days, p.o.

Ahmad MK, Mahdi AA, Shukla KK, Islam N, Rajender S, Madhukar D, Shankhwar SN, Ahmad S. *Withania somnifera* improves semen quality by regulating reproductive hormone levels and oxidative stress in seminal plasma of infertile males. *Fertil Steril.* 2010;94:989-996.

Alam N, Hossain M, Mottalib Md A, Sulaiman SA, Gan SH, Khalil Md I. Methanolic extracts of *Withania somnifera* leaves,

fruits and roots possess antioxidant properties and antibacterial activities. *BMC Complement Altern Med.* 2012;12:175.

Al-Ani N, Hadi SA, Nazar R. Antimicrobial activities of *Withania somnifera* Crude extract. *Sci Agri.* 2013;4:74-76.

Amaravathi P, Srilatha C, Ramadevi V, Sujatha K. Immunomodulatory effect of *Withania somnifera*

- (ashwagandha) against fenvalerate induced immunotoxicity. *Int J Pharm Biol Sci.* 2012;3:B10-B16.
- Ambiye VR, Langade D, Dongre S, Aptikar P, Kulkarni M, Dongre A. Clinical Evaluation of the Spermatogenic Activity of the Root Extract of Ashwagandha (*Withania somnifera*) in Oligospermic Males: A Pilot Study. *Evid Based Complement Alternat Med.* 2013;2013:571420.
- Anwer T, Sharma M, Pillai KK, Iqbal M. Effect of *Withania somnifera* on insulin sensitivity in non-insulin-dependent diabetes mellitus rats. *Basic Clin Pharmacol Toxicol.* 2008;102:498-503.
- Baitharu I, Jain V, Deep SN, Hota KB, Hota SK, Prasad D, Ilavazhagan G. *Withania somnifera* root extract ameliorates hypobaric hypoxia induced memory impairment in rats. *J Ethnopharmacol.* 2013;145:431-441.
- Bhatnagar M, Sharma D, Salvi M. Neuroprotective Effects of *Withania somnifera* Dunal.: A Possible Mechanism. *Neurochem Res.* 2009;34:1975-1983.
- Bhattacharya SK, Bhattacharya A, Sairam K., Ghosal S. Anxiolytic-antidepressant activity of *Withania somnifera* glycowithanolides: an experimental study. *Phytomedicine.* 2000;7:463-469.
- Bhattacharya SK, Muruganandam AV. Adaptogenic activity of *Withania somnifera*: An experimental study using a rat model of chronic stress. *Pharmacol Biochem Behav.* 2003;75:547-555.
- Bone K. Clinical Applications of Ayurvedic and Chinese Herbs: Monographs for the Western Herbal Practitioner. (Warwick, Australia: Phytotherapy Press), 1996.
- Choudhary MI, Yousuf S, Rahman AU. Withanolides: Chemistry and Antitumor Activity. In *Natural Products*. Ramawat KG, Me ´rillon JM ed. (Berlin, Heidelberg: Springer-Verlag), pp. 3465-3495, 2013.
- Devi PU, Sharada AC, Solomon FE, Kamath MS. *In vivo* growth inhibitory effect of *Withania somnifera* (Ashwagandha) on a transplantable mouse tumor Sarcoma 180. *Ind J Exp Biol.* 1992;30:169-172.
- Elsakka M, Grigorescu E, Stănescu U, Stănescu U, Dorneanu V. New data referring to chemistry of *Withania somnifera* species. *Rev Med Chir Soc Med Nat Iasi.* 1990;94:385-387.
- Gardner Z, McGuffin M. American Herbal Products Association's Botanical Safety Hand Book. (Florida, United States: CRC Press, Taylor & Francis Group), 2013.
- Girdhari LG, Avtar CR. Synergistic effect of *Withania somnifera* dunal and L-dopa in the inhibition of haloperidol-induced catalepsy in mice. *Phcog Mag.* 2009;19:46-50.
- Grover A, Shandilya A, Agrawal V, Bisaria VS, Sundar D. Computational evidence to inhibition of human acetyl cholinesterase by withanolide A for Alzheimer treatment. *J Biomol Struct Dyn.* 2012;29:651-662.
- Gupta A, Mahdi AA, Shukla KK, Ahmad MK, Bansal N, Sankhwar P, Sankhwar SN. Efficacy of *Withania somnifera* on seminal plasma metabolites of infertile males: a proton NMR study at 800 MHz. *J Ethnopharmacol.* 2013;149:208-214.
- Gupta A, Singh S. Evaluation of anti-inflammatory effect of *Withania somnifera* root on collagen-induced arthritis in rats. *Pharm Biol.* 2014;52:308-320.
- Hahm ER, Moura MB, Kelley EE, Houten BV, Shiva S, Singh SV. Withaferin-A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. *PLoS One.* 2011;6:e23354.
- Hahm ER, Singh SV. Withaferin-A-induced apoptosis in human breast cancer cells is associated with suppression of inhibitor of apoptosis family protein expression. *Cancer Lett.* 2013;334:101-108.
- Hepper FN. Old World *Withania* (Solanaceae): A taxonomic review and key to the species. In *Solanaceae III: Taxonomy, Chemistry, Evolution*. In Kew Bulletin. Hawkes, Lester, Nee, Estrada eds. (London, English: Royal Botanic Gardens Kew and Linnean Society), pp.785-788, 1991.
- Hina S, Rehman KU, Dogar ZUH, Jahan N, Hameed M, Khan ZI, Ahmad K, Mukhtar K, Valeem E. Cardioprotective effect of gemmotherapeutically treated *Withania somnifera* against chemically induced myocardial injury. *Pak J Bot.* 2010;42:1487-1499.
- Hosny MH, Farouk HH. Protective effect of *Withania somnifera* against radiation-induced hepatotoxicity in rats. *Ecotoxicol Environ Saf.* 2012;80:14-19.
- Ilayperuma I, Ratnasooriya WD, Weerasooriya TR. Effect of *Withania somnifera* root extract on the sexual behaviour of male rats. *Asian J Androl.* 2002;4:295-298.
- Jayanthi MK, Prathima C, Huralikuppi JC, Suresha RN, Dhar M. Anti-depressant effects of *Withania somnifera* fat (Ashwagandha ghrutha) extract in experimental mice. *Int J Pharm Bio Sci.* 2012;3:33.
- Joshi P, Misra L, Siddique AA, Srivastava, Kumar S, Darokar MP. Epoxide group relationship with cytotoxicity in withanolide derivatives from *Withania somnifera*. *Steroids.* 2014;79:19-27.
- Kapoor S. *Withania somnifera* and its emerging anti-neoplastic effects. *Inflammopharmacology.* 2014;22:67.
- Kataria H, Shah N, Kaul SC, Wadhwa R, Kaur G. Water Extract of Ashwagandha Leaves Limits Proliferation and Migration, and Induces Differentiation in Glioma Cells. *Evid Based Complement Alternat Med.* 2011;2011:267614.
- Kataria H, Wadhwa R, Kaul SC, Kaur G. Water Extract from the Leaves of *Withania somnifera* Protect RA Differentiated C6 and IMR-32 Cells against Glutamate-Induced Excitotoxicity. *PLoS One.* 2012;7:e37080.
- Khalili M. The Effect of Oral Administration of *Withania somnifera* Root on Formalin-Induced Pain in Diabetic Rats. *Basic Clin Neurosci.* 2009;1:29-31.
- Khan ZA, Ghosh AR. L-Arginine abolishes the anxiolytic-like effect of withaferin-A in the elevated plus-maze test in rats. *Afr J Pharm Pharmacol.* 2011;5:234-237.

- Khedgikar V, Kushwaha P, Gautam J, Verma A, Changkija B, Kumar A, Sharma S, Nagar GK, Singh D, Trivedi PK, Sangwan NS, Mishra PR, Trivedi R. Withaferin A: a proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone. *Cell Death Dis.* 2013;4:e778.
- Koduru S, Kumar R, Srinivasan S, Evers MB, Damodaran C. Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. *Mol Cancer Ther.* 2010;9:202-210.
- Ku SK, Bae JS. Antiplatelet, anticoagulant, and profibrinolytic activities of withaferin-A. *Vascul Pharmacol.* 2014;60:120-126.
- Ku SK, Han MS, Bae JS. Withaferin-A is an inhibitor of endothelial protein C receptor shedding *in vitro* and *in vivo*. *Food Chem Toxicol.* 2014;68:23-29.
- Kuboyama T, Tohda C, Komatsu K. Neuritic regeneration and synaptic reconstruction induced by withanolide A. *Br J Pharmacol.* 2005;144:961-971.
- Kulkarni SK, Akula KK, Dhir A. Effect of *Withania somnifera* Dunal root extract against pentylenetetrazol seizure threshold in mice: possible involvement of GABAergic system. *Indian J Exp Biol.* 2008;46:465-469.
- Kulkarni SK, Dhir A. *Withania somnifera*: An Indian ginseng. *Prog Neuropsychopharmacol Biol Psychiatry.* 2008;32:1093-1105.
- Kurapati KRV, Atluri VSR, Samikkannu T, Nair MPN. Ashwagandha (*Withania somnifera*) Reverses β -Amyloid 1-42 Induced Toxicity in Human Neuronal Cells: Implications in HIV-Associated Neurocognitive Disorders (HAND). *PLoS One.* 2013;8:e77624.
- Lavie D, Glotter E, Shvo Y. Constituents of *Withania somnifera* Dun III. The side chain of withaferin A. *J Org Chem.* 1965;30:1774-1778.
- Mabberley DJ. Mabberley's Plant-Book: a portable dictionary of plants, their classification and uses. (Cambridge, England: Cambridge University Press), 2008.
- Maity T, Adhikari A, Bhattacharya K, Biswas S, Debnath PK, Maharana CS. A study on evaluation of antidepressant effect of Imipramine adjunct with Aswagandha and Brahmi. *Nepal Med College J.* 2011;13:250-253.
- Malik T, Pandey DK, Dogra N. Ameliorative Potential of Aqueous Root Extract of *Withania somnifera* Against Paracetamol Induced Liver Damage in Mice. *Pharmacologia.* 2013;4:89-94.
- Manjunath M J, Muralidhara. Effect of *Withania somnifera* supplementation on rotenone-induced oxidative damage in cerebellum and striatum of the male mice brain. *Cent Nerv Syst Agents Med Chem.* 2013;13:43-56.
- Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazón J. Steroidal Lactones from *Withania somnifera*, an Ancient Plant for Novel Medicine. *Molecules.* 2009;14:2373-2393.
- Mishra LC, Singh BB. Scientific Basis for the Therapeutic Use of *Withania somnifera* (Ashwagandha): A Review. *Altern Med Rev.* 2000;5:334-346.
- Mohanty I, Arya DS, Dinda A, Talwar KK, Joshi S, Gupta SK. Mechanisms of cardioprotective effect of *Withania somnifera* in experimentally induced myocardial infarction. *Basic Clin Pharmacol Toxicol.* 2004;94:184-190.
- Motiwalla HF, Bazzill J, Samadi A, Zhang H, Timmermann BN, Cohen MS, Aubé J. Synthesis and Cytotoxicity of Semisynthetic Withalongolide A Analogues. *ACS Med Chem Lett.* 2013;4:1069-1073.
- Mulabagal V, Subbaraju GV, Rao CV, Sivaramakrishna C, DeWitt DL, Holmes D, Sung B, Aggarwal BB, Tsay HS, Nair MG. Withanolide Sulfoxide from Aswagandha Roots Inhibits Nuclear Transcription Factor-Kappa-B, Cyclooxygenase and Tumor Cell Proliferation. *Phytother Res.* 2009;22: 987-992.
- Muralikrishnan G, Amanullah S, Basha MI, Dinda AK, Shakeel F. Modulating effect of *Withania somnifera* on TCA cycle enzymes and electron transport chain in azoxymethane-induced colon cancer in mice. *Immunopharmacol Immunotoxicol.* 2010a;32:523-527.
- Muralikrishnan G, Dinda AK, Shakeel F. Immunomodulatory effects of *Withania somnifera* on azoxymethane induced experimental colon cancer in mice. *Immunol Invest.* 2010b;39:688-698.
- Mwitari PG, Ayeka PA, Ondicho J, Matu EN, Bii CC. Antimicrobial activity and probable mechanisms of action of medicinal plants of Kenya: *Withania somnifera*, *Warbugia ugandensis*, *Prunus africana* and *Plectranthus barbatus*. *PlosOne.* 2013;8:e65619.
- Nema R, Khare S, Jain P, Pradhan A. Anticancer activity of *Withania somnifera* (leaves) flavonoids compound. *Int J Pharm Sci Rev Res.* 2013;19:103-106.
- Oh JH, Kwon TK. Withaferin-A inhibits tumor necrosis factor alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. *Int Immunopharmacol.* 2009;9:614-619.
- Padmavathi B, Rath PC, Rao AR, Singh RP. Roots of *Withania somnifera* inhibit forestomach and skin carcinogenesis in mice. *Evid Based Complement Alternat Med.* 2005;2:99-105.
- Pandit S, Chang KW, Jeon JG. Effects of *Withania somnifera* on the growth and virulence properties of *Streptococcus mutans* and *Streptococcus sobrinus* at sub-MIC levels. *Anaerobe.* 2013;19:1-8.
- Pant M, Ambwani T, Umaphathi V. Antiviral Activity of Ashwagandha Extract on Infectious Bursal Disease Virus Replication. *Ind J Sci Tech.* 2012;5:2750-2751.
- Patel K, Singh RB, Patel DK. Pharmacological and analytical aspects of withaferin-A: A concise report of current scientific literature. *Asia Pac J Reproduction.* 2013;2:238-243.
- Paval J, Kaitheri SK, Potu BK, Govindan S, Kumar RS, Narayanan SN, Moorkoth S. Comparing the anti-arthritis activities of the plants *Justicia gendarussa* Burm F. and *Withania somnifera* Linn. *Int J Green Pharm.* 2009;3:281-284.

- Pingali U, Pilli R, Fatima N. Effect of standardized aqueous extract of *Withania somnifera* on tests of cognitive and psychomotor performance in healthy human participants. *Pharmacognosy Res.* 2014;6:12-18.
- Prabu PC, Panchapakesan S, Raj CD. Acute and sub-acute oral toxicity assessment of the hydroalcoholic extract of *Withania somnifera* roots in Wistar rats. *Phytother Res.* 2013;27:1169-1178.
- Puri HS. *Rasayana: Ayurvedic Herbs for Longevity and Rejuvenation (Traditional Herbal Medicines for Modern Times)*. 1st ed. (London, England: CRC press), 2002.
- RajaSankar S, Manivasagam T, Sankar V, Prakash S, Muthusamy R, Krishnamurti A, Surendran S. *Withania somnifera* root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse. *J Ethnopharmacol.* 2009;125:369-373.
- Roy RV, Suman S, Das TP, Luevano JE, Damodaran C. Withaferin-A, a steroidal lactone from *Withania somnifera*, induces mitotic catastrophe and growth arrest in prostate cancer cells. *J Nat Prod.* 2013;76:1909-1915.
- Sabina EP, Chandel S, Rasool MK. Evaluation of analgesic, antipyretic and ulcerogenic effect of Withaferin-A. *Int J Integr Biol.* 2009;6:52-56.
- Sabina EP, Rasool M, Vedi M, Navaneethan D, Ravichander M, Parthasarthy P, Thella SR. Hepatoprotective and antioxidant potential of *Withania somnifera* against paracetamol-induced liver damage in rats. *Int J Pharmacy Pharm Sci.* 2013;5:648-651.
- Sachdeva H, Sehgal R, Kaur S. Studies on the protective and immunomodulatory efficacy of *Withania somnifera* along with cisplatin against experimental visceral leishmaniasis. *Parasitol Res.* 2013;112:2269-2280.
- Sandhu JS, Shah B, Shenoy S, Chauhan S, Lavekar GS, Padhi MM. Effects of *Withania somnifera* (Ashwagandha) and *Terminalia arjuna* (Arjuna) on physical performance and cardiorespiratory endurance in healthy young adults. *Int J Ayurveda Res.* 2010;1:144-149.
- Santhi N, Aishwarya S. Insights from the molecular docking of withanolide derivatives to the target protein PknG from *Mycobacterium tuberculosis*. *Bioinformation.* 2011;7:1-4.
- Sarangi A, Jena S, Sarangi AK, Swain B. Anti-diabetic effects of *Withania somnifera* root and leaf extracts on streptozotocin induced diabetic rats. *J Cell Tissue Res.* 2013;13:3597.
- Scalbert A. Antimicrobial properties of tannins. *Phytochem.* 1991;30:3875-3883.
- Schliebs R, Liebmann A, Bhattacharya SK, Kumar A, Ghosal S, Bigl V. Systemic administration of defined extracts from *Withania somnifera* (Indian Ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. *Neurochem Int.* 1997;30:181-190.
- Sehgal N, Gupta A, Valli RK, Datt Joshi S, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V. *Withania somnifera* reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. *Proc Natl Acad Sci USA.* 2012;109:3510-3515.
- Shahriar M, Alam F, Uddin MMN. Analgesic and neuropharmacological activity of *Withania somnifera* root. *Int J Pharm.* 2014;4:203-208.
- Sharada AC, Emerson Solomon F, Uma Devi P. Toxicity of *Withania somnifera* root extract in rats and mice. *Pharm Biol.* 1993;31:205-212.
- Sharma S, Sharma V, Pracheta, Sharma S. Therapeutic potential of hydromethanolic root extract of *Withania somnifera* on neurological parameters in swiss albino mice subjected to lead nitrate. *Int J Curr Pharm Res.* 2011;3:52-56.
- Sharma U, Velpandian T, Sharma P, Singh S. Evaluation of anti-leishmanial activity of selected Indian plants known to have antimicrobial properties. *Parasitol Res.* 2009;105:1287-1293.
- Shenoy S, Chaskar U, Sandhu JS, Paadhi MM. Effects of eight-week supplementation of Ashwagandha on cardiorespiratory endurance in elite Indian cyclists. *J Ayurveda Integr Med.* 2012;3:209-214.
- Shimmi SC, Jahan N, Sultana N. Effect of Ashwagandha (*Withania somnifera*) root extract against gentamicin induced changes of serum urea and creatinine levels in rats. *J Bangladesh Soc Physiol.* 2011;6:84-89.
- Shukla KK, Mahdi AA, Mishra V, Rajender S, Sankhwar SN, Patel D, Das M. *Withania somnifera* improves semen quality by combating oxidative stress and cell death and improving essential metal concentrations. *Reprod Biomed Online.* 2011;22:421-427.
- Singariya P, Mourya KK, Kumar P. Antimicrobial activity of the crude extracts of *Withania somnifera* and *Cenchrus setigerus* in vitro. *Phcog J.* 2012;4:60-65.
- Singh B, Saxena AK, Chandan BK, Gupta DK, Bhutani KK, Anand KK. Adaptogenic activity of a novel, withanolide free aqueous fraction from the roots of *Withania somnifera* Dun. *Phytother Res.* 2001;15:311-318.
- Singh G, Kumar P. Antibacterial potential of alkaloids of *Withania somnifera* L. & *Euphorbia hirta* L. *Int J Pharmacy Pharm Sci.* 2012;4:78-81.
- Singh G, Kumar P. Evaluation of antimicrobial efficacy of flavonoids of *Withania somnifera* L. *Indian J Pharm Sci.* 2011;73:473-478.
- Singh N, Verma P, Pandey BR, Gilca M. Role of *Withania somnifera* in prevention and treatment of cancer: An overview. *Int J Pharm Sci Drug Res.* 2011;3:274-279.
- Singh SP, Tanwer BS, Khan M. Antifungal potential of ashwagandha against some pathogenic fungi. *Int J Biopharm.* 2010;1:72-74.
- Soman S, Anju TR, Jayanarayanan S, Antony S, Paulose CS. Impaired motor learning attributed to altered AMPA receptor function in the cerebellum of rats with temporal lobe epilepsy: ameliorating effects of *Withania somnifera* and withanolide A.

Epilepsy Behav. 2013;27:484-491.

Soman S, Korah PK, Jayanarayanan S, Mathew J, Paulose CS. Oxidative stress induced NMDA receptor alteration leads to spatial memory deficits in temporal lobe epilepsy: ameliorative effects of *Withania somnifera* and withanolide A. Neurochem Res. 2012;37:1915-1927.

Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, Liu Y, Tighiouart M, Vertino PM, Harvey RD, Garcia A, Marcus AI. Withaferin-A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer. 2011;129:2744-2755.

Udayakumar R, Kasthuriangan S, Mariashibu TS, Rajesh M, Anbazhagan VR, Kim SC, Ganapathi A, Choi CW. Hypoglycaemic and hypolipidaemic effects of *Withania somnifera* root and leaf extracts on alloxan-induced diabetic rats. Int J Mol Sci. 2009;10:2367-2382.

Um HJ, Min KJ, Kim DE, Kwon TK. Withaferin-A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells. Biochem Biophys Res Commun. 2012;427:24-29.

Varma D, Kumar R, Namboothiri INN. Synthesis of withasomnines and their non-natural analogues from aldehydes and 4-Nitro-1-butanol in three steps. J Org Chem. 2013;78:3482-3486.

Visavadiya NP, Narasimhacharya AV. Hypocholesteremic and antioxidant effects of *Withania somnifera* (Dunal) in hypercholesteremic rats. Phytomedicine. 2007;14:136-142.

Wadhwa R, Singh R, Gao R, Shah N, Widodo N, Nakamoto T, Ishida Y, Terao K, Kaul SC. Water extract of Ashwagandha leaves has anticancer activity: identification of an active component and its mechanism of action. PLoS One. 2013;8:e77189.

Wijeratne EM, Xu YM, Scherz-Shouval R, Marron MT, Rocha DD, Liu MX, Costa-Lotufo LV, Santagata S, Lindquist S, Whitesell L, Gunatilaka AA. Structure-activity relationships for withanolides as inducers of the cellular heat-shock response. J Med Chem. 2014;57:2851-2863.

Yadav B, Bajaj A, Saxena M, Saxena AK. *In vitro* anticancer activity of the Root, stem and leaves of *Withania somnifera* against various human cancer cell lines. Indian J Pharm Sci. 2010;72:659-663.

Yang H, Wang Y, Cheryan VT, Wu W, Cui CQ, Polin LA, Pass HI, Dou QP, Rishi AK, Wali A. Withaferin A inhibits the proteasome activity in mesothelioma *in vitro* and *in vivo*. PLoS One. 2012;7:e41214.

Yang Z, Garcia A, Xu S, Powell DR, Vertino PM, Singh S, Marcus AI. *Withania somnifera* root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition. PLoS One. 2013;8:e75069.

Yu Y, Hamza A, Zhang T, Gu M, Zou P, Newman B, Li Y, Gunatilaka AA, Zhan CG, Sun D. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol. 2010;79:542-551.